Gelonghui September 24th, sh pharma (02607.HK) announced that its holding subsidiary Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd. (hereinafter referred to as 'Jinzhu') has received the 'Drug Supplementary Application Approval Notice' issued by the National Medical Products Administration (referred to as the 'NMPA') (Notice Number: 2024B02634), changing the holder of the oral solution of sulfobutyl ether sodium to Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd.
上海医药(02607.HK)：子公司成为氨磺必利口服溶液上市许可持有人
sh pharma (02607.HK): Subsidiary becomes the holder of the marketing authorization for Ammonium Sulfate Oral Solution.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated